Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy

BACKGROUND: Targeted disease-modifying antirheumatic drug (DMARD) options for rheumatoid arthritis (RA) include tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) or alternative mechanisms of action (MOAs), such as a T-cell co-stimulation modulator (...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Am Health Drug Benefits
Prif Awduron: Bonafede, Machaon M. K., McMorrow, Donna, Proudfoot, Clare, Shinde, Shraddha, Kuznik, Andreas, Chen, Chieh-I
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Engage Healthcare Communications, LLC 2018
Pynciau:
Business
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207310/
https://ncbi.nlm.nih.gov/pubmed/30464787
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg